KYTX
Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
−0.68%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 13.63x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.19x
- Price / sales
- —
- Price / cash flow
- -2.28x
Enterprise value
- Enterprise value
- $195.4M
- EV / sales
- —
- EV / EBITDA
- -1.31x
- EV / EBIT
- -1.23x
- Market cap
- $361.8M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026